Clinical trial of immunomodulatory therapy using anti-thymocyte globulin and pegfilgrastim for recently onset type 1 diabetes
Not Applicable
- Conditions
- Type 1 diabetes
- Registration Number
- JPRN-UMIN000027070
- Lead Sponsor
- Toyama University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1. Active infection 2. Pregnancy/breast-feeding 3. Past history of malignant tumor 4. Interstitial pneumonia 5. Severe liver or/and kidney dysfunction 6. Past history of ATG administration 7. Under systemic steroid therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of adverse events during 52 weeks of the treatment or observation
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ATG and PeG-CSF immunomodulation in type 1 diabetes?
How does ATG/PeG-CSF therapy compare to standard-of-care in recent-onset T1D patients?
Which biomarkers predict response to ATG and PeG-CSF in type 1 diabetes treatment?
What are the potential adverse events associated with ATG/PeG-CSF immunotherapy for T1D?
Are there combination approaches using ATG/PeG-CSF with other immunomodulators for T1D treatment?